Elotuzumab
Aliases
BMS-901608, Empliciti, HuLuc63, HuLuc-63, PDL063 (1 other aliases)
19 clinical trials
7 abstracts
12 indications
Indication
Multiple MyelomaIndication
Multiple Myeloma in RelapseIndication
Plasma Cell LeukemiaIndication
Essential ThrombocythemiaIndication
Polycythemia VeraIndication
Post-Polycythemic Myelofibrosis PhaseIndication
Primary MyelofibrosisIndication
Smoldering MyelomaIndication
Smoldering Plasma Cell MyelomaIndication
DS Stage I Plasma Cell MyelomaIndication
Stage III Plasma Cell MyelomaClinical trial
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Status: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-09-29
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.Org: Yale School of Public Health, Yale University Shool of Medicine,
Clinical trial
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted TherapiesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-06-04
Clinical trial
An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-12-15
Clinical trial
A Multicenter Phase 1-DEC (Dose Expansion Cohort) Open-label Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaStatus: , Estimated PCD: 2024-08-01
Clinical trial
A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With MyelofibrosisStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaStatus: Completed, Estimated PCD: 2018-12-12
Clinical trial
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)Status: Active (not recruiting), Estimated PCD: 2020-02-01
Clinical trial
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple MyelomaStatus: Terminated, Estimated PCD: 2021-02-18
Clinical trial
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMMStatus: Active (not recruiting), Estimated PCD: 2029-08-01
Clinical trial
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and LenalidomideStatus: Recruiting, Estimated PCD: 2026-04-23
Abstract
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.Org: Clinica São Germano, São Paulo, Brazil, General Hospital Evangelismos, Athens, Greece, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary, Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, GSK, Upper Providence, PA,
Abstract
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, The Second Affiliated Hospital of Xi'an Jiaotong University,
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.Org: Schleswig-Holstein University Hospital, Hospital Salzburg Paracelus University, University Hospital rechts der Isar, Jena University Hospital, Wuerzburg University Medical Center,
Abstract
Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,